Aurinia Pharmaceuticals Inc. (AUPH)

6.13
NASDAQ : Health Technology
Prev Close 6.27
Day Low/High 6.12 / 6.31
52 Wk Low/High 5.06 / 7.85
Avg Volume 573.20K
Exchange NASDAQ
Shares Outstanding 78.45M
Market Cap 575.04M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Aurinia Issues Letter To Shareholders

Aurinia Issues Letter To Shareholders

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today sent a letter to shareholders in connection with the Company's upcoming Annual General Meeting of Shareholders ("AGM") to be held on Wednesday, June 26, 2019.

Aurinia Pharmaceuticals To Present At Upcoming Investor Conferences

Aurinia Pharmaceuticals To Present At Upcoming Investor Conferences

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that Mr.

Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting Of Shareholders

Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting Of Shareholders

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), today filed its Notice of Meeting and Management Information Circular.

First Week Of AUPH January 2020 Options Trading

First Week Of AUPH January 2020 Options Trading

Investors in Aurinia Pharmaceuticals Inc saw new options begin trading this week, for the January 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Aurinia Pharmaceuticals To Present At The RBC Capital Markets Global Healthcare Conference

Aurinia Pharmaceuticals To Present At The RBC Capital Markets Global Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that Mr.

Aurinia Reports First Quarter 2019 Financial Results And Recent Operational Highlights

Aurinia Reports First Quarter 2019 Financial Results And Recent Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) ("Aurinia" or the "Company") today reported financial results for the first quarter ended March 31, 2019 and provided an update on recent operational highlights.

Aurinia Recognizes World Lupus Day And Lupus Awareness Month With Activities Focused On Raising Awareness For Lupus Nephritis

Aurinia Recognizes World Lupus Day And Lupus Awareness Month With Activities Focused On Raising Awareness For Lupus Nephritis

In recognition of Lupus Awareness Month and World Lupus Day, Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals To Release First Quarter 2019 Financial Results On May 14, 2019

Aurinia Pharmaceuticals To Release First Quarter 2019 Financial Results On May 14, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that it will release its first quarter 2019 financial results on Tuesday, May 14, 2019, after the market closes.

Aurinia Further Strengthens Its Board Of Directors With The Appointment Of Dr. Daniel Billen

Aurinia Further Strengthens Its Board Of Directors With The Appointment Of Dr. Daniel Billen

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" or the "Company"), a clinical stage biopharmaceutical company focused on the global immunology market, today announced it has appointed Dr.

Aurinia Pharmaceuticals To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals To Present At The 2019 Bloom Burton & Co. Healthcare Investor Conference

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that members of the management team will present a corporate overview at the 2019 Bloom Burton & Co.

Aurinia Announces Appointment Of Peter Greenleaf As Chief Executive Officer And Board Director And The Elevation Of Dr. George M. Milne, Jr. To Chairman Of The Board

Aurinia Announces Appointment Of Peter Greenleaf As Chief Executive Officer And Board Director And The Elevation Of Dr. George M. Milne, Jr. To Chairman Of The Board

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company"), a late clinical-stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Mr.

First Week Of May 17th Options Trading For Aurinia Pharmaceuticals (AUPH)

First Week Of May 17th Options Trading For Aurinia Pharmaceuticals (AUPH)

Investors in Aurinia Pharmaceuticals Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AUPH options chain for the new May 17th contracts and identified the following call contract of particular interest.

The Fed Decision Will Be a Market Mover No Matter What

The Fed Decision Will Be a Market Mover No Matter What

Computer algorithms will trigger volatility even if there is no surprise news.

Aurinia Reports Fourth Quarter And Full Year 2018 Financial Results And Operational Highlights

Aurinia Reports Fourth Quarter And Full Year 2018 Financial Results And Operational Highlights

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) ("Aurinia" or the "Company") today reported its financial results for the fourth quarter and year ended December 31, 2018.

Aurinia Recognizes World Kidney Day And National Kidney Month With New Activities Focused On Raising Awareness For Kidney Disease

Aurinia Recognizes World Kidney Day And National Kidney Month With New Activities Focused On Raising Awareness For Kidney Disease

In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals To Release Fourth Quarter And Full Year 2018 Financial Results On March 19, 2019

Aurinia Pharmaceuticals To Release Fourth Quarter And Full Year 2018 Financial Results On March 19, 2019

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes.

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

What's Keeping You Up?: Cramer's 'Mad Money' Recap (Wednesday 2/27/19)

Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Waste Management, Weight Watchers, Centene: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.

Aurinia Closes At-The-Market Facility

Aurinia Closes At-The-Market Facility

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the " Company") today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market ("ATM") offerings of common...

China and Biotech Stocks Are Running Hot

China and Biotech Stocks Are Running Hot

If you are an index trader it is a tough call, but for stock-pickers it remains a very good trading market.

Aurinia Receives Notice Of Allowance From The US Patent And Trademark Office For Claims Directed To Its Novel Voclosporin Dosing Protocol For Lupus Nephritis

Aurinia Receives Notice Of Allowance From The US Patent And Trademark Office For Claims Directed To Its Novel Voclosporin Dosing Protocol For Lupus Nephritis

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/ TSX:AUP) (the "Company" or "Aurinia"), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that it has received a Notice of Allowance from the United States Patent...

Aurinia To Present At The 8th Annual SVB Leerink Global Healthcare Conference New York City

Aurinia To Present At The 8th Annual SVB Leerink Global Healthcare Conference New York City

Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and Chief Executive Officer, Richard M.

Trading Notes for Select Stocks

Trading Notes for Select Stocks

Here's my take on a list of stocks I've been watching.

The Action in Select Small Caps Is Encouraging

The Action in Select Small Caps Is Encouraging

It's tough to do much while we await major news events.

There Are a Number of Justifications For Friday's Market Strength

There Are a Number of Justifications For Friday's Market Strength

Regardless of what is moving the markets, it is a good example of how you have to focus on price action above all else.

December 20th Options Now Available For Aurinia Pharmaceuticals (AUPH)

December 20th Options Now Available For Aurinia Pharmaceuticals (AUPH)

Investors in Aurinia Pharmaceuticals Inc saw new options become available today, for the December 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 329 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.